Mineralys Therapeutics, Inc. (MLYS) Financials

MLYS Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 652.9 million 14.7 million
Dec. 31, 2025 661.8 million 15.1 million
Sept. 30, 2025 599.9 million 23.5 million
June 30, 2025 335.7 million 22.2 million

MLYS Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -39.5 million 6.5 million
Dec. 31, 2025 -37.9 million 5.3 million
Sept. 30, 2025 -28.9 million 5.8 million
June 30, 2025 -30.2 million 4.6 million

MLYS Net Income

No data available :(

MLYS Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 646.1 million - -
Dec. 31, 2025 656.6 million - -
Sept. 30, 2025 217.6 million - -
June 30, 2025 324.9 million - -

MLYS Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 82.8 million
Dec. 31, 2025 80.5 million
Sept. 30, 2025 70.6 million
June 30, 2025 65.5 million

MLYS Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 24.4 million 21.0 million -
Dec. 31, 2025 15000 24.4 million 13.9 million -
Sept. 30, 2025 - 31.5 million 9.7 million -
June 30, 2025 - 38.3 million 8.5 million -

MLYS Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 6000
Dec. 31, 2025 - 13000
Sept. 30, 2025 - 15000
June 30, 2025 - 16000

MLYS

Price: $23.92

52 week price:
12.59
47.65

Earnings Per Share: -1.97 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 1.7 billion

Links: